-
Mashup Score: 0Biliary actinomycosis mimicking common hepatic duct cancer - 3 hour(s) ago
A 45-year-old woman was admitted urgently with right upper abdominal pain and mechanical jaundice (total bilirubin 2.6 mg/dL). Transabdominal ultrasonography raised concerns about calculous cholecystitis and common bile duct stones. ERCP revealed a proximal common hepatic duct (CHD) stricture without stones (A). Cholangioscopy (SpyGlass DSII; Boston Scientific Corporation [BSC], Marlborough, Mass, USA) confirmed a semicircular dense stricture. Additionally, an unknown 3- to 4-mm whitish hollow formation was seen in the right hepatic duct (B).
Source: www.giejournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4Best practices for nonampullary duodenal lesions - 7 hour(s) ago
Drs. Simon Lo and Koushik Das discuss key updates for treating nonampullary duodenal lesions.
Source: www.youtube.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Looking at Disease Course and Mortality in MASH Patients - 7 hour(s) ago
A new study of patients with MASH shows a six-year mortality rate of 10% in patients with compensated cirrhosis.
Source: www.gastroendonews.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies - 8 hour(s) ago
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated interferon alpha (PegIFN-α) has represented the only therapeutic option, with limited virological response rates and poor tolerability. In 2020, the European Medicines Agency approved bulevirtide (BLV) at 2 mg/day, an entry inhibitor of hepatitis B virus (HBV)/hepatitis delta virus (HDV), which proved to be safe and effective as a monotherapy for up to 144 weeks in clinical trials and real-life studies, including patients with cirrhosis. Long-term BLV monotherapy may reduce decompensating events in patients with cirrhosis. The combination of BLV 2 mg with PegIFN-α increased the HDV RNA undetectability rates on-therapy but not off-therapy, compared with PegIFN monotherapy. However, combination therapy, but not BLV monotherapy, may induce hepatitis B surface antigen (HBsAg) loss in some patients. The PegIFN lambda study has be
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1
TMEs of IM and MO identified by whole-exome sequencing at single-cell resolution. Approach and Results: We performed parallel whole-exome sequencing and scRNA-seq on 23 samples from 7 patients to profile their TMEs when major results were validated by immunohistochemistry in the additional cohort. Integrative analysis of whole-exome sequencing and single-cell RNA sequencing found that malignant cells in IM showed higher intratumor heterogeneity, stemness, and more activated metabolism than those in MO. Tumors from IM shared similar TMEs while distinct TMEs were noticed in those from MO. Furthermore, CD20+ B cells, plasma cells, and conventional type II dendritic cells (cDC2s) were decreased in IM relative to MO while T cells in IM exhibited a more terminally exhausted capacity with a higher proportion of proliferative/exhausted T cells than that in MO. Both CD20 and CD1C correlated with better prognosis in multifocal HCC. Additionally, MMP9+ tumor-associated macrophages were enriched a
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2
croenvironment in PVTT. Approach & Results: Time-of-flight mass cytometry (CyTOF) revealed that macrophages and monocytes were the dominant immune cell type in PVTT, with a higher proportion than in primary tumor (PT) and blood (54.1% vs. 26.3% and 9.1%, p<0.05). The differentially enriched clustering of inhibitory and regulatory immune cells in PVTT indicated an immune-suppressive environment. According to the single-cell RNA sequencing (scRNA-seq), TAM-C5AR1 was characterized by leukocyte chemotaxis and was the most common subpopulation in PVTT (36.7%). Multiple immunofluorescence staining showed that the C5aR+ TAM/Mφ were enriched in PVTT compared to both PT and liver, and positively correlated with C5a (r=0.559, p<0.001). Notably, THP-1 (monocyte cell line) was recruited by CSQT2 (PVTT cell line) and exhibited up-regulation of CD163, CD206, and PD-L1 upon stimulation. C5aR antagonist could reverse this. C5aR+ TAMs could also inhibit Granzyme B in CD8+ T cells. High infiltration of
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2
mall surface viral antigen. Approach and Results: C57BL/6 mice were transduced with adeno-associated virus-HBV and were treated twice a week with HBV broadly neutralizing antibodies for 5 weeks. A DNA-based vaccine encoding the HBV core, envelope, and polymerase proteins was administered once to mice 3 weeks after initiating antibody therapy. The antiviral effects and antigen-specific immune responses were evaluated before and for 8 weeks after therapeutic vaccination. Vaccine administration with or without antibody treatment induced the development of functional HBV-specific CD8+ T cells and envelope-specific resident memory T cells in the liver. The combination of antibody treatment and DNA vaccination enhanced the recruitment of B and CD8+ T lymphocytes into the liver of HBV-carrier mice 2 weeks after vaccination. However, although still detectable 2 months after vaccination, HBV-specific CD8+ T cells showed an exhausted phenotype, suggesting that they are dysfunctional. In contrast
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet-
Artículo Original Inmunidad específica contra el virus de la hepatitis B es potenciada combinando terapia con anticuerpos neutralizantes y vacunación con ADN en un modelo murino de infección crónica por el virus de la hepatitis B Beretta et al. https://t.co/UHoAvfaEKk #LiverX https://t.co/FxRN0i9kIj
-
-
Mashup Score: 0Stard1 promotes cholestatic liver injury and disease... : Hepatology - 10 hour(s) ago
inly via the classic pathway and in a lower proportion through the mitochondrial acidic pathway. The latter requires STARD1-dependent cholesterol transport to the mitochondrial inner membrane for metabolism, whose contribution to BA-induced hepatotoxicity and CLD is unknown. Approach and Results: Here we show that patients with primary biliary cholangitis exhibit increased expression of STARD1 compared to control subjects. Mice with hepatocyte-specific Stard1 deletion (Stard1Δhep) were more resistant to experimental models of complete (bile duct ligation, BDL) and chemical obstructive cholestasis-induced liver injury, inflammation and fibrosis than Stard1f/f mice. Stard1Δhep mice exhibited reduced hepatic BAs and mitochondrial cholesterol accumulation but increased mitochondrial GSH (mGSH) levels following BDL compared to Stard1f/f mice. Pharmacological mGSH depletion sensitized primary mouse hepatocytes to a mix of BAs mimicking the profile seen in Stard1f/f mice after BDL leading to
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4
Background GI cancers pose an increasing global health burden, with their impact on the working-age population (WAP) aged 15–64 years remaining largely unexplored despite the crucial role of this group in societal and economic well-being. Objective To assess trends and cross-country inequality in the global burden of six GI cancers from 1990 to 2021 among individuals in the WAP. Design The 2021 Global Burden of Disease study dataset was used to obtain estimates of GI cancer incidence and 95% uncertainty intervals, including the number of cases, crude incidence rate and age-standardised incidence rate (ASIR). WAP GI cancer epidemiology was assessed at the national, regional and global levels, evaluating trends from 1990 to 2021 from overall, local and Sociodemographic Index (SDI) perspectives and using standard health equity methods to quantify cross-country inequality. Results Colorectal cancer exhibited the greatest burden of GI cancer among the WAP in 2021. From 1990 to 2021, the num
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1
To cite: Elurbide J, Colyn L, Latasa MU, et al. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma. Gut 2025;74:116-127.Read the full arti…
Source: www.youtube.comCategories: General Medicine News, GastroenterologyTweet
At the Focal Point, Anishchenko et al find "Biliary actinomycosis mimicking common hepatic duct cancer." https://t.co/nkvSP8cVHO #GITwitter #GIEJournal https://t.co/E6EmVQn30D